Nuvalent CFO Sells $1.2M in Shares

Insider sale represents 11.79% decrease in executive's position

Apr. 3, 2026 at 10:26pm

Got story updates? Submit your updates here. ›

An extreme close-up of intricate, heavy-duty banking equipment and machinery in shades of grey, blue, and black, conveying the institutional power and security of the financial sector as a conceptual representation of an insider stock transaction.An insider stock sale by Nuvalent's CFO highlights the complex financial machinery powering the biotech industry.San Diego Today

Nuvalent, Inc. (NASDAQ:NUVL) Chief Financial Officer Alexandra Balcom sold 11,430 shares of the company's stock on April 1st, 2026 for a total transaction value of $1,202,550.30. The sale represented an 11.79% decrease in Balcom's ownership stake in the clinical-stage precision oncology company.

Why it matters

Insider transactions, particularly sales by executives, can provide insight into a company's performance and management's confidence in its future prospects. This sale by Nuvalent's CFO may raise questions about the company's short-term outlook, despite its promising pipeline of targeted cancer therapies.

The details

Balcom sold the shares at an average price of $105.21 per share. Following the transaction, she still owns 85,533 shares in Nuvalent, valued at nearly $9 million. The CFO has made several other stock sales in recent months, including transactions in January 2026 that netted over $700,000.

  • The shares were sold on Wednesday, April 1st, 2026.
  • In January 2026, Balcom sold 3,181 shares for $309,065.96 and 4,236 shares for $412,247.52.

The players

Alexandra Balcom

Chief Financial Officer of Nuvalent, Inc.

Nuvalent, Inc.

A clinical-stage precision oncology company focused on developing targeted therapies for patients with genetically defined cancers.

Got photos? Submit your photos here. ›

What’s next

Investors will likely monitor any further insider transactions at Nuvalent to gauge management's confidence in the company's outlook.

The takeaway

While insider sales can raise questions, Nuvalent's promising pipeline of targeted cancer therapies and strong institutional backing suggest the company remains well-positioned for growth, despite this recent CFO transaction.